 |
21 Diseases |  |
1 Trial |
|
1 Trial |  |
18 News |  |
- | SNB-101 / SN BioSci
Journal: Generation of anti-SN38 antibody for loading efficacy and therapeutic monitoring of SN38-containing therapeutics. (Pubmed Central) - Jul 18, 2024
However, it has garnered significant scientific interest as a payload in conjugated nanomedicine platforms (e.g., SN-38lip, NK012, SNB-101, and ADCs) to enhance their effectiveness and safety...The immunization efficiency, reactivity, binding affinity, specificity, and cross-reactivity of purified pAb and mAb against Irinotecan, a model for the emergence of an SN38 derivative in clinical settings, were evaluated using ELISA and western blotting (WB) techniques...The affinity of both pAb and mAb also meets the acceptance criteria for quantifying SN38 in fluidic material, as well as in Therapeutic drug monitoring (TDM) studies, a crucial aspect of personalized medicine. The potential applications of the anti-SN38 antibodies extend to reducing SN38-induced systemic toxicity through an inverse targeting strategy, a novel approach that piques further interest in our findings.
- | NK012 / Nippon Kayaku
Clinical, P2 data, Journal: A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients. (Pubmed Central) - Aug 30, 2019
NK012 monotherapy yielded an RR similar to the RR of irinotecan monotherapy that was reported in the phase III EPIC trial (4.2%), and the incidence of grade ≥ 3 diarrhea was low. Based on the incidence and severity of febrile neutropenia and grade ≥ 3 neutropenia, the initial dose of NK012 28 mg/m may be too high for colorectal cancer patients who have previously been treated with an oxaliplatin-based chemotherapy regimen.
- | NK012 / Nippon Kayaku, irinotecan / Generic mfg.
Journal: A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle. (Pubmed Central) - Feb 7, 2017
The recommended phase II dose of NK012 for UGT1A1 wt/wt and wt/*28 genotype patients is 28 mg/m(2) every 28 days. Additional clinical development as a single agent in specific patient populations or in combination with other chemotherapy agents is warranted.
- |||| NK012 / Nippon Kayaku
Trial completion, Metastases: A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Feb 19, 2015
P2, N=61, Completed, Sponsor: Nippon Kayaku Co.,Ltd.
Additional clinical development as a single agent in specific patient populations or in combination with other chemotherapy agents is warranted. Active, not recruiting --> Completed
- || NK012 / Nippon Kayaku
Trial primary completion date, Metastases: A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Nov 13, 2014
P2, N=61, Active, not recruiting, Sponsor: Nippon Kayaku Co.,Ltd.
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Dec 2014
- | NK012 / Nippon Kayaku
Trial completion, Combination therapy, Metastases: Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer (clinicaltrials.gov) - Nov 13, 2014
P1, N=35, Completed, Sponsor: Nippon Kayaku Co.,Ltd.
Trial primary completion date: Dec 2013 --> Dec 2014 Active, not recruiting --> Completed
- NK012 / Nippon Kayaku
Enrollment change, Combination therapy, Metastases: Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer (clinicaltrials.gov) - Mar 17, 2013
P1, N=4, Completed, Sponsor: Nippon Kayaku Co.,Ltd.
Active, not recruiting --> Completed N=35 --> 4
- NK012 / Nippon Kayaku
Enrollment closed, Combination therapy, Metastases: Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer (clinicaltrials.gov) - Mar 17, 2013
P1, N=35, Active, not recruiting, Sponsor: Nippon Kayaku Co.,Ltd.
N=35 --> 4 Recruiting --> Active, not recruiting
- ||| NK012 / Nippon Kayaku
Enrollment closed, Metastases: A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Mar 17, 2013
P2, N=61, Active, not recruiting, Sponsor: Nippon Kayaku Co.,Ltd.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- NK012 / Nippon Kayaku
Trial completion, Combination therapy, Metastases: Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer (clinicaltrials.gov) - Mar 17, 2013
P1, N=4, Completed, Sponsor: Nippon Kayaku Co.,Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| NK012 / Nippon Kayaku
Trial completion: A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer (clinicaltrials.gov) - Mar 17, 2013
P2, N=72, Completed, Sponsor: Nippon Kayaku Co.,Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NK012 / Nippon Kayaku
Trial completion: Study of NK012 in Patients With Refractory Solid Tumors (clinicaltrials.gov) - Mar 17, 2013
P1, N=39, Completed, Sponsor: Nippon Kayaku Co.,Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed